Compare Sanofi SA (SNY) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Xylem, Inc. — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while Xylem, Inc. trades at $120.79 (market cap $28.67B). The key difference: Sanofi SA is far larger — about 3.7× Xylem, Inc.'s market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| SNY | XYL | |
|---|---|---|
Market Cap | $104.83B | $28.67B |
Sector | Health | Industrials |
52-Week High | $52.34 | $152.95 |
52-Week Low | $41.33 | $106.34 |
Enterprise Value | $121.32B | $29.92B |
Dividend Yield | 5.5% | 1.43% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
